M7824: A promising new strategy to combat cancer immune evasion.
作者信息
Gatti-Mays Margaret E, Gulley James L
机构信息
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Oncoscience. 2018 Aug 22;5(11-12):269-270. doi: 10.18632/oncoscience.451. eCollection 2018 Nov.
Abstract
摘要
相似文献
1
M7824: A promising new strategy to combat cancer immune evasion.M7824：一种对抗癌症免疫逃逸的有前景的新策略。
Oncoscience. 2018 Aug 22;5(11-12):269-270. doi: 10.18632/oncoscience.451. eCollection 2018 Nov.
2
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.抗程序性死亡配体1/转化生长因子β受体2（M7824）融合蛋白诱导人膀胱癌细胞系的免疫原性调节，使其更容易受到免疫介导的识别和裂解。
Urol Oncol. 2018 Mar;36(3):93.e1-93.e11. doi: 10.1016/j.urolonc.2017.09.027. Epub 2017 Nov 2.
3
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.M7824，一种同时靶向 PD-L1 和 TGF-β的双功能融合蛋白，增强了抗肿瘤的临床前活性。
Sci Transl Med. 2018 Jan 17;10(424). doi: 10.1126/scitranslmed.aan5488.
4
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.M7824是一种新型双功能抗程序性死亡配体1/转化生长因子β（PD-L1/TGFβ）陷阱融合蛋白，作为单一疗法以及与疫苗联合使用时均能提高抗肿瘤疗效。
Oncoimmunology. 2018 Feb 14;7(5):e1426519. doi: 10.1080/2162402X.2018.1426519. eCollection 2018.
5
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.双靶 TGF-β 和 PD-L1 的双功能抗 PD-L1/TGF-βRII 制剂：临床前和临床进展现状。
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000433.
6
Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.抗 PD-L1/TGF-βR 融合蛋白（SHR-1701）克服了肺癌中淋巴细胞恢复紊乱引起的对 PD-1/PD-L1 抑制剂的耐药性。
Cancer Commun (Lond). 2022 Jan;42(1):17-36. doi: 10.1002/cac2.12244. Epub 2022 Jan 3.
7
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.靶向 PD-L1 降解的 ANXA1 衍生肽抑制多种癌症中的肿瘤免疫逃逸。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006345.
8
TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.TGFβ 通过激活 AKT-Smad3-SHP1 轴拮抗 IFNγ 介导的肺腺癌适应性免疫逃逸。
Cancer Res. 2023 Jul 5;83(13):2262-2277. doi: 10.1158/0008-5472.CAN-22-3009.
9
Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.转化生长因子β调控肿瘤来源外泌体中 PD-L1 的富集，并调节乳腺癌中 TCR 信号转导早期磷酸化，从而介导 CD8 T 细胞功能障碍。
Carcinogenesis. 2021 Feb 11;42(1):38-47. doi: 10.1093/carcin/bgaa092.
10
The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation.通过基因编辑建立 B 细胞缺陷型 Igh-J KO 小鼠模型及其疗效评估。
Int Immunopharmacol. 2023 Mar;116:109704. doi: 10.1016/j.intimp.2023.109704. Epub 2023 Jan 21.
引用本文的文献
1
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer.癌症中靶向PD-1/PD-L1的多特异性抗体
BioDrugs. 2025 May;39(3):427-444. doi: 10.1007/s40259-025-00712-6. Epub 2025 Mar 19.
2
Knowledge mapping of immunotherapy in cervical carcinoma: a bibliometric analysis (2000-2023).免疫治疗宫颈癌的知识图谱：文献计量分析（2000-2023 年）。
Front Immunol. 2024 Jan 9;14:1328103. doi: 10.3389/fimmu.2023.1328103. eCollection 2023.
3
Inhibition of Transforming Growth Factor Beta and Immune Checkpoints Induces a Distinctively Distributed, Severe Bullous Pemphigoid.抑制转化生长因子β和免疫检查点可诱发一种分布独特的严重大疱性类天疱疮。
Acta Derm Venereol. 2021 Jun 30;101(6):adv00489. doi: 10.2340/00015555-3853.
4
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.联合免疫疗法提高晚期乳腺癌的胜算：晚期乳腺癌中疫苗、免疫检查点抑制剂、化疗和组蛋白去乙酰化酶抑制剂的逐步添加
Front Oncol. 2021 Mar 5;10:581801. doi: 10.3389/fonc.2020.581801. eCollection 2020.
5
Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response.抗原密度和免疫抑制因子对抗体融合蛋白和双特异性抗体介导的 T 细胞反应的肿瘤靶向共刺激的影响。
Cancer Immunol Immunother. 2020 Nov;69(11):2291-2303. doi: 10.1007/s00262-020-02624-6. Epub 2020 Jun 5.
6
The Use of a Humanized NSG-β2m Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa.使用人源化NSG-β2m模型研究双功能免疫治疗药物bintrafusp alfa介导的免疫和抗肿瘤作用。
Front Oncol. 2020 Apr 21;10:549. doi: 10.3389/fonc.2020.00549. eCollection 2020.
7
miR-20a-5p/TGFBR2 Axis Affects Pro-inflammatory Macrophages and Aggravates Liver Fibrosis.微小RNA-20a-5p/转化生长因子β受体2轴影响促炎性巨噬细胞并加重肝纤维化。
Front Oncol. 2020 Feb 13;10:107. doi: 10.3389/fonc.2020.00107. eCollection 2020.
8
Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cancer Therapies to the Clinic.2019年美国波士顿蛋白质工程峰会（PEGS）亮点：推动基于抗体的癌症疗法进入临床应用。
Antib Ther. 2019 Oct;2(4):79-87. doi: 10.1093/abt/tbz010. Epub 2019 Dec 3.
本文引用的文献
1
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.M7824是一种新型双功能抗程序性死亡配体1/转化生长因子β（PD-L1/TGFβ）陷阱融合蛋白，作为单一疗法以及与疫苗联合使用时均能提高抗肿瘤疗效。
Oncoimmunology. 2018 Feb 14;7(5):e1426519. doi: 10.1080/2162402X.2018.1426519. eCollection 2018.
2
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.TGFβ 驱动基因重建的结肠癌转移中的免疫逃逸。
Nature. 2018 Feb 22;554(7693):538-543. doi: 10.1038/nature25492. Epub 2018 Feb 14.
3
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.TGFβ 通过促使 T 细胞排除而减弱肿瘤对 PD-L1 阻断的反应。
Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14.
4
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.M7824，一种同时靶向 PD-L1 和 TGF-β的双功能融合蛋白，增强了抗肿瘤的临床前活性。
Sci Transl Med. 2018 Jan 17;10(424). doi: 10.1126/scitranslmed.aan5488.
5
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.M7824（MSB0011359C）的 I 期临床试验，一种双功能融合蛋白，靶向 PD-L1 和 TGFβ，用于晚期实体瘤。
Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3.
6
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.一种新型双功能抗PD-L1/TGF-β陷阱融合蛋白（M7824）可有效逆转人肺癌细胞的间充质化。
Oncoimmunology. 2017 Jul 13;6(10):e1349589. doi: 10.1080/2162402X.2017.1349589. eCollection 2017.
7
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.抗程序性死亡配体1/转化生长因子β受体2（M7824）融合蛋白诱导人膀胱癌细胞系的免疫原性调节，使其更容易受到免疫介导的识别和裂解。
Urol Oncol. 2018 Mar;36(3):93.e1-93.e11. doi: 10.1016/j.urolonc.2017.09.027. Epub 2017 Nov 2.
8
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).抗PD-L1/TGFβR2双特异性融合蛋白（M7824）的功能分析
Oncotarget. 2017 Sep 8;8(43):75217-75231. doi: 10.18632/oncotarget.20680. eCollection 2017 Sep 26.
Zotero 插件